An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai
Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.
“This is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,” said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.
The stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.
Age-related macular degeneration affects upward of 15 million Americans. It occurs when the small central portion of the retina, known as the macula, deteriorates. The retina is the light-sensing nerve tissue at the back of the eye. Macular degeneration may also be caused by environmental factors, aging and a genetic predisposition.
When animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer. This protective layer prevented ongoing degeneration of the vital retinal cells responsible for vision.
Cedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body. In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.
“These induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,” said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study. “Though additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.”
The Latest on: Age-Related Macular Degeneration
via Google News
The Latest on: Age-Related Macular Degeneration
- Allergan/AbbVie’s Macular Degeneration Drug Rejected by FDAon June 26, 2020 at 9:59 pm
The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.
- FDA issues CRL to wet AMD drug from Allergan, Molecular Partnerson June 26, 2020 at 4:46 pm
The FDA sent a complete response letter (CRL) to Allergan plc, an Abbvie Inc. company, and Molecular Partners AG, of Zurich, Switzerland, regarding the BLA for abicipar pegol, their VEGF-A ...
- Eye Inflammation Dooms AbbVie Wet AMD Drug to an FDA Rejectionon June 26, 2020 at 3:14 pm
The FDA has rejected an investigational AbbVie drug for the “wet” form of age-related macular degeneration, dealing a setback to the company’s bid to ...
- FDA Rejects AbbVie's Macular Degeneration Drug Abicipar Pegolon June 26, 2020 at 3:11 pm
The drug, which AbbVie gained in its acquisition of Allergan, was supposed to be a growth driver for the company.
- Management and Visual Outcomes of Acute Bacterial Endophthalmitis Following Intravitreal Injection of Contaminated Bevacizumab in a Single Dayon June 26, 2020 at 12:19 pm
BACKGROUND AND OBJECTIVE:Bevacizumab requires compounding for off-label intravitreal injection, thus creating a risk of possible contamination during preparation.PATIENTS AND METHODS:This ...
- FDA rejects AbbVie's eye drug, citing safety concernson June 26, 2020 at 9:52 am
The drug, abicipar, was supposed to challenge market-leading drugs like Regneron's Eylea. But inner eye inflammation seen in clinical trials appear to have sunk its chances.
- Regeneron vows ‘vigorous’ defense against allegations it paid kickbacks for eye drugon June 26, 2020 at 7:29 am
The U.S. district attorney for Massachusetts filed suit against the drugmaker this week, alleging that it paid tens of millions in kickbacks through a copay foundation for Eylea, a drug used to treat ...
- AbbVie's Allergan, Molecular Partners hit by FDA eye drug rejectionon June 26, 2020 at 12:36 am
AbbVie is learning that this week after its buyout of Allergan has seen, just a month after finalizing the deal with the Federal Trade Commission’s blessing, that one of the first drugs it might have ...
- Macular Degeneration Treatment Market to Proliferate at a Healthy CAGR of 7.3% by 2027on June 23, 2020 at 2:53 am
The global Macular Degeneration Treatment Market size is expected to reach USD 11.4 billion by 2027, at a significant growth rate of 6.6 % during the forecasted period 2020 to 2027. The market report ...
- Plastic membrane to treat age-related macular degenerationon June 19, 2020 at 7:51 am
A porous polymeric scaffold might be the answer to a sight problem that afflicts millions of older people every year, age-related macular degeneration. Researchers writing in the International Journal ...
via Bing News